How 3SBio became China’s most watched biotech firm after the Pfizer deal
3SBio is now at the center of global oncology focus after licensing SSGJ-707 to Pfizer. Explore what’s driving its stock surge and strategic ascent. Read More
Pfizer’s $6.05bn bet on oncology innovation: Inside the 3SBio SSGJ-707 licensing deal
Find out how Pfizer’s $6.05B deal with 3SBio could reshape the global cancer immunotherapy market with PD-1/VEGF bispecific SSGJ-707. Read More
Deadly blast hits Shenyang market days after President Xi’s visit
A catastrophic explosion rocked the Shenyang Dadong Food Mall in northeast China’s Liaoning Province on January 26, 2025, leaving a grim aftermath just as the ... Read More